Pharmacyclics has received clearance from the Food and Drug Administrationto begin phase-one clinical trials to investigate the safety andutility of its gadolinium-texaphyrin agent for MRI contrast andradiation therapy applications.
Pharmacyclics has received clearance from the Food and Drug Administrationto begin phase-one clinical trials to investigate the safety andutility of its gadolinium-texaphyrin agent for MRI contrast andradiation therapy applications.
Gadolinium-texaphyrin is an expanded porphyrin compound thatdiffers from current extracellular contrast media in that it hasbeen shown to enter cancer cells selectively, according to theSunnyvale, CA, company.
Gadolinium-texaphyrin is the second Pharmacyclics MRI agentto enter human clinical studies and the first agent based on thecompany's texaphyrin technology. Another Pharmacyclics agent,Gadolite, is well into phase-three clinical studies, the companysaid.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.